Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - [Docket No. FDA-2024-N-1636]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

# SUMMARY:

The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that KEBILIDI (eladocagene exuparvovec-tneq), approved on November 13, 2024, manufactured by PTC Therapeutics Inc., meets the criteria for a priority review voucher.

# FOR FURTHER INFORMATION CONTACT:

Myrna Hanna, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911.

# SUPPLEMENTARY INFORMATION:

FDA is announcing the issuance of a priority review voucher to the sponsor of an approved rare pediatric disease product application. Under section 529 of the FD&C Act (21 U.S.C. 360ff), FDA will award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA has determined that KEBILIDI (eladocagene exuparvovec-tneq), manufactured by PTC Therapeutics Inc., meets the criteria for a priority review voucher. KEBILIDI (eladocagene exuparvovec-tneq) is indicated for treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase deficiency.

                    For further information about the Rare Pediatric Disease Priority Review Voucher Program and for a link to the full text of section 529 of the FD&C Act, go to                     *https://www.fda.gov/​industry/​developing-products-rare-diseases-conditions/​rare-pediatric-disease-rpd-designation-and-voucher-programs.*                     For further information about KEBILIDI (eladocagene exuparvovec-tneq), go to the Center for Biologics Evaluation and Research's Approved Cellular and Gene Therapy Products website at                     *https://www.fda.gov/​vaccines-blood-biologics/​      ( print page 95220)    cellular-gene-therapy-products/​approved-cellular-and-gene-therapy-products.*

Dated: November 26, 2024.

P. Ritu Nalubola,

Associate Commissioner for Policy.

[FR Doc. 2024-28206 Filed 11-29-24; 8:45 am]

BILLING CODE 4164-01-P